When to update COVID-19 vaccine composition

Rebecca Grant^#¹, Jilian A Sacks^#¹, Priya Abraham², Supamit Chunsuttiwat³, Cheryl Cohen^{4

5}, J Peter Figueroa⁶, Thomas Fleming⁷, Paul Fine⁸, David Goldblatt⁹, Hideki Hasegawa¹⁰, C Raina MacIntrye¹¹, Ziad A Memish^{12

13}, Elizabeth Miller¹⁴, Sergio Nishioka¹⁵, Amadou A Sall¹⁶, Samba Sow¹⁷, Oyewale Tomori¹⁸, Youchun Wang¹⁹, Maria D Van Kerkhove¹, Marie-Ange Wambo¹, Homa Attar Cohen²⁰, Samuel Mesfin²⁰, James R Otieno¹, Lorenzo Subissi¹, Sylvie Briand²¹, David E Wentworth²², Kanta Subbarao^{23

24}

Affiliations

¹ Department of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland.
² Indian Council of Medical Research - National Institute of Virology, Pune, India.
³ Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
⁴ Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
⁵ School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁶ University of West Indies, Mona, Jamaica.
⁷ Department of Biostatistics, University of Washington, Seattle, WA, USA.
⁸ London School of Hygiene and Tropical Medicine, London, UK.
⁹ Great Ormond Street Institute of Child Health, University College London, London, UK.
¹⁰ Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, Japan.
¹¹ Biosecurity Program, The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
¹² Research and Innovation Centre, King Saud Medical City, Ministry of Health and College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
¹³ Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
¹⁴ Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
¹⁵ Independent Consultant, Brasilia, Brazil.
¹⁶ Institut Pasteur de Dakar, Dakar, Senegal.
¹⁷ Centre for Vaccine Development, Ministry of Health, Bamako, Mali.
¹⁸ African Centre of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Nigeria.
¹⁹ Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, China.
²⁰ Department of Acute Response Coordination, World Health Organization, Geneva, Switzerland.
²¹ Department of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland. briands@who.int.
²² Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
²³ WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
²⁴ Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Victoria, Australia.

^# Contributed equally.

PMID: 36807683
DOI: 10.1038/s41591-023-02220-y

When to update COVID-19 vaccine composition

Rebecca Grant et al. Nat Med. 2023 Apr.

. 2023 Apr;29(4):776-780.

doi: 10.1038/s41591-023-02220-y.

Authors

Affiliations

¹ Department of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland.
² Indian Council of Medical Research - National Institute of Virology, Pune, India.
³ Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
⁴ Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
⁵ School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁶ University of West Indies, Mona, Jamaica.
⁷ Department of Biostatistics, University of Washington, Seattle, WA, USA.
⁸ London School of Hygiene and Tropical Medicine, London, UK.
⁹ Great Ormond Street Institute of Child Health, University College London, London, UK.
¹⁰ Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, Japan.
¹¹ Biosecurity Program, The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
¹² Research and Innovation Centre, King Saud Medical City, Ministry of Health and College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
¹³ Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
¹⁴ Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
¹⁵ Independent Consultant, Brasilia, Brazil.
¹⁶ Institut Pasteur de Dakar, Dakar, Senegal.
¹⁷ Centre for Vaccine Development, Ministry of Health, Bamako, Mali.
¹⁸ African Centre of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Nigeria.
¹⁹ Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, China.
²⁰ Department of Acute Response Coordination, World Health Organization, Geneva, Switzerland.
²¹ Department of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland. briands@who.int.
²² Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
²³ WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
²⁴ Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Victoria, Australia.

^# Contributed equally.

PMID: 36807683
DOI: 10.1038/s41591-023-02220-y

No abstract available

PubMed Disclaimer

References

1. World Health Organization. https://www.who.int/activities/tracking-SARS-CoV-2-variants (accessed August 2022).
1. Higdon, M. M. et al. Lancet Infect. Dis. 22, 1114–1116 (2022). - DOI - PubMed - PMC
1. World Health Organization. https://www.who.int/groups/technical-advisory-group-on-covid-19-vaccine-... (accessed August 2022).
1. World Health Organization. https://www.who.int/publications/m/item/who-target-product-profiles-for-... (accessed August 2022).
1. Subissi, L. et al. Nat. Med. 28, 1110–1115 (2022). - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

Grants and funding

001/WHO_/World Health Organization/International

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

When to update COVID-19 vaccine composition

Affiliations

When to update COVID-19 vaccine composition

Authors

Affiliations

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical